If passed, TROA would: Permanently allow Medicare Part D to cover FDA-approved anti-obesity medications Expand Medicare Part B coverage of intensive behavioral therapy for obesity to include a wider range of providers (not just primary care physicians) However, in April 2025, CMS announced it would not include Medicare Part D coverage of obesity drugs in its rule changes for 2026, stating the proposal was "not appropriate at this time." That decision pushed the issue back to Congress, where the TROA remains under consideration
Every input from secondary sources, primary interviews, and the internal database was brought together and triangulated
Therefore, the researchers posited that food intake may have been increased in the Ipamorelin groups
Lets explore some of the history of DTC for weight loss interventions and, then, for subscribers only, you can read my personal opinions about GLP-1s and predictions about their future
White says that when clients ask about creatine, I usually have to start by debunking some myths. Number one on the Myths List
[DOI] [PMC free article] [PubMed] [Google Scholar] 104.Sun KH, de Pablo Y, Vincent F, Shah K